Scalper1 News
Swiss pharma giant Roche (RHHBY) was a rare drug stock moving up Monday after its U.S. biotech arm Genentech said its drug candidate succeeded against primary progressive multiple sclerosis (PPMS) in a clinical trial. Roche said its drug ocrelizumab had met the late-stage study’s primary endpoint of showing significantly reduced progression of clinical disability, compared with the placebo group, after 12 weeks of treatment. It will reveal more Scalper1 News
Scalper1 News